Balversa (erdafitinib) has been recommended for use on the NHS as the first and only treatment in the UK for urothelial cancer (UC) involving a fibroblast growth factor receptor (FGFR3) alteration, which affects up to one in five patients with advanced disease. The drug slows tumour growth, advancing time in treatment and improving quality of life.
Eligible patients will have unresectable or metastatic disease and will have previously received at least one line of therapy containing a programmed death receptor-1 or programmed death-ligand inhibitor…
